Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2
about
Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin.Cytoplasmic interactions of syndecan-4 orchestrate adhesion receptor and growth factor receptor signallingVersican degradation and vascular diseaseSelectivity in glycosaminoglycan binding dictates the distribution and diffusion of fibroblast growth factors in the pericellular matrix.Impact of heparanase on renal fibrosisSpecificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinaseN-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor bindingFibroblast growth factors as tissue repair and regeneration therapeutics.Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomasThe occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamineRegulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfateThe mutual impact of syndecan-1 and its glycosaminoglycan chains--a multivariable puzzle.Heparanase and hepatocellular carcinoma: promoter or inhibitor?Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.Versatile role of heparanase in inflammationAngiopoietin-3 is tethered on the cell surface via heparan sulfate proteoglycansEndogenous synthesis of n-3 polyunsaturated fatty acids in Fat-1 mice is associated with increased mammary gland and liver syndecan-1.The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease.Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections.SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma.Extracellular superoxide dismutase protects cardiovascular syndecan-1 from oxidative shedding.Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice.Heparan sulfate mediates trastuzumab effect in breast cancer cellsClinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer.Heparan sulfate proteoglycans.FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cellsMacrophage polarization in pancreatic carcinoma: role of heparanase enzyme.Epithelial expression and release of FGF-2 from heparan sulphate binding sites in bronchial tissue in asthma.Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells.The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival.Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant.FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice.Bovine lactoferricin is anti-inflammatory and anti-catabolic in human articular cartilage and synoviumShedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data.Interaction of human papillomavirus type 16 particles with heparan sulfate and syndecan-1 molecules in the keratinocyte extracellular matrix plays an active role in infection.Chemical synthesis of a heparan sulfate glycopeptide: syndecan-1.Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
P2860
Q24303785-20725257-A588-453B-8C04-DB49CA7B0195Q24534902-C0188FE2-051D-4B69-916B-89F5746361C0Q24600539-9797030B-3906-42A4-89D7-1D54EC8236C4Q27336444-668CAA33-D560-4DD6-A160-950FE3FBE832Q28083753-E2E0AA8E-DEEE-43E9-8322-CDDCD42E3A37Q28144405-DABBA67A-AB30-46BB-84C9-0305B9777EDAQ28250986-81E2FE3F-A5FB-4151-BC50-4E33B5D3FFBBQ28272364-4764B331-421E-4693-88FA-B1283E6CC29AQ28344801-CCAC83AC-0A5F-4059-B2C3-1D56AC50E3E7Q28594700-B0A9BE50-63A0-465C-AE76-DEC5A58310ABQ28748799-638DA7DD-3AB1-4C08-80BC-275B4D8FA97FQ33354119-29C33272-8C5B-4F07-B4C8-B31BB36F64CEQ33596487-FBFFCD19-223A-485C-8E25-A33861B80B2BQ33647915-BCE4427F-2DE9-4F13-950F-55857DA434E6Q33770777-AE101E7E-AB97-4045-8208-31AFD642F4BEQ33914700-6407AA08-BF8B-499F-9CF2-E11F9B364A4CQ33927026-D0F1E052-A781-46F4-8A6D-F1CD1458B1E6Q34022649-27A34FEA-2609-4712-8380-EABE8B164459Q34114308-BB24E599-2B0A-43C7-AB3E-2C2A23050AF0Q34162277-13177956-42A7-44A9-A34B-55F4741CBD3AQ34694466-9F886360-E5C8-48F4-BB95-EFE0A4A57048Q34762351-A7D3054A-1DE4-46E9-A712-C683B971D7B1Q34762358-EA74D536-4A93-4463-A0BC-EA9F5C054323Q34876266-7C000099-2449-4AC3-980C-D0E7CE2CE7C6Q35003529-441617C4-755D-4472-AEEF-D6EE6EFDA679Q35010790-4A52C8CC-C778-41BE-8046-A92D06B43490Q35059448-CECF93F4-5B5A-45A7-BDAA-E9F23A032884Q35082690-434E910B-0E15-47D9-971B-BAAFFC930E3BQ35102577-A5DC22D4-6B48-48E1-A88B-84EAADD84AA9Q35536802-904AFC33-FF88-4BAB-90D6-2DCBFC3357B4Q35668839-3835D86E-0632-49AD-A083-872DD7504253Q35820525-5DF99495-73BC-4EF0-A1CD-2B7F173727DAQ35886513-EB8A25E9-ADB0-46C8-BADF-23C3D3CA6C48Q36259459-95C0C11F-7C59-45E0-81AB-D2BDC5571E8FQ36295868-F62849E4-04A1-455D-98CB-C14B641C6500Q36316404-ED2C6D4C-285B-4261-98BE-A919E58EDCF0Q36339725-56807DC5-678A-42AF-941C-87D9315626E5Q36376623-0DEBEE4A-62EF-4581-84F0-7ED92E044EA0Q36452712-9B61E3B2-20EE-47FC-B148-AAB262B3843DQ36499443-C07C8B30-B3F2-4C6D-B2AC-ED96E07BFCEC
P2860
Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Physiological degradation conv ...... to a potent activator of FGF-2
@ast
Physiological degradation conv ...... to a potent activator of FGF-2
@en
Physiological degradation conv ...... to a potent activator of FGF-2
@nl
type
label
Physiological degradation conv ...... to a potent activator of FGF-2
@ast
Physiological degradation conv ...... to a potent activator of FGF-2
@en
Physiological degradation conv ...... to a potent activator of FGF-2
@nl
prefLabel
Physiological degradation conv ...... to a potent activator of FGF-2
@ast
Physiological degradation conv ...... to a potent activator of FGF-2
@en
Physiological degradation conv ...... to a potent activator of FGF-2
@nl
P2093
P2860
P3181
P356
P1433
P1476
Physiological degradation conv ...... to a potent activator of FGF-2
@en
P2093
D M Ornitz
M Bernfield
M L Fitzgerald
S Ledbetter
V Kainulainen
P2860
P2888
P3181
P356
10.1038/NM0698-691
P407
P577
1998-06-01T00:00:00Z